Sébastien Bolze
Poxel SA (France) · 36 works · 1,866 citations · h-index 20
Top works
- HPLC determination of ketamine, norketamine, and dehydronorketamine in plasma with a high-purity reversed-phase sorbent
- Mechanism of action of Imeglimin: A novel therapeutic agent for type 2 diabetes
- Imeglimin Normalizes Glucose Tolerance and Insulin Sensitivity and Improves Mitochondrial Function in Liver of a High-Fat, High-Sucrose Diet Mice Model
- Analysis of drug transporter expression in human intestinal Caco‐2 cells by real‐time PCR
- Imeglimin increases glucose‐dependent insulin secretion and improves β‐cell function in patients with type 2 diabetes
- Imeglimin prevents human endothelial cell death by inhibiting mitochondrial permeability transition without inhibiting mitochondrial respiration
- Development of an in Vitro Screening Model for the Biosynthesis of Acyl Glucuronide Metabolites and the Assessment of Their Reactivity toward Human Serum Albumin
- Imeglimin amplifies glucose-stimulated insulin release from diabetic islets via a distinct mechanism of action
- Use of simulated intestinal fluid for Caco-2 permeability assay of lipophilic drugs
- Imeglimin lowers glucose primarily by amplifying glucose-stimulated insulin secretion in high-fat-fed rodents
- Evaluation of PXL065 – deuterium-stabilized (R)-pioglitazone in patients with NASH: A phase II randomized placebo-controlled trial (DESTINY-1)
- Imeglimin preserves islet β‐cell mass in Type 2 diabetic ZDF rats
- Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic fatty liver disease (STAMP-NAFLD): a randomised, double-blind, placebo-controlled, phase 2a study
- Deuterium‐Stabilized (R)‐Pioglitazone (PXL065) Is Responsible for Pioglitazone Efficacy in NASH yet Exhibits Little to No PPARγ Activity
- In VitroPrimary Human and Animal Cell-Based Blood−Brain Barrier Models as a Screening Tool in Drug Discovery
- Direct AMPK Activation Corrects NASH in Rodents Through Metabolic Effects and Direct Action on Inflammation and Fibrogenesis
- In Vitro Investigation, Pharmacokinetics, and Disposition of Imeglimin, a Novel Oral Antidiabetic Drug, in Preclinical Species and Humans
- Reduced lactic acidosis risk with Imeglimin: Comparison with Metformin
- Imeglimin Does Not Induce Clinically Relevant Pharmacokinetic Interactions When Combined with Either Metformin or Sitagliptin in Healthy Subjects
- Imeglimin population pharmacokinetics and dose adjustment predictions for renal impairment in Japanese and Western patients with type 2 diabetes